Mechanisms of Vascular Calcification Through Mineral Stress Signaling

Abstract

Vascular calcification (VC) is a pathophysiological process characterized by the deposition of mineral salts within the vascular wall, significantly contributing to increased cardiovascular risk, especially among patients with chronic kidney disease (CKD), diabetes mellitus, and advanced age. Recent research has highlighted the central role of mineral stress signaling pathways in the initiation and progression of VC. This review synthesizes current evidence on the epidemiology, underlying mechanisms, risk factors, clinical presentation, diagnostic approaches, management strategies, emerging therapies, and guideline-based recommendations concerning VC, with a particular focus on the molecular and cellular pathways of mineral stress signaling. The review aims to provide clinicians and researchers with a comprehensive understanding of the mechanistic basis of VC and its clinical implications, supporting improved patient management and fostering further research in this rapidly evolving field.

Introduction

Vascular calcification is the pathological deposition of calcium-phosphate mineral complexes within arterial walls, affecting both the intimal and medial layers. It is recognized as a major contributor to arterial stiffness, left ventricular hypertrophy, impaired coronary perfusion, and increased all-cause and cardiovascular mortality. While historically considered a passive process, recent advances have elucidated the active, cell-mediated nature of VC, driven by complex signaling pathways responsive to mineral imbalances. The phenomenon of mineral stress signaling has emerged as a critical mediator, linking systemic mineral dysregulation to local vascular pathology. This article explores these mechanisms in detail, emphasizing their clinical and therapeutic relevance.

Epidemiology / Disease Burden

VC is highly prevalent among patients with CKD, with studies reporting rates exceeding 80% in end-stage renal disease (ESRD) populations. It is also commonly observed in individuals with diabetes mellitus, metabolic syndrome, and older adults. The burden of VC extends beyond its frequency, as it independently predicts adverse cardiovascular outcomes and mortality. Epidemiological data from large cohort studies, such as the Multi-Ethnic Study of Atherosclerosis (MESA), have established a graded relationship between the extent of vascular calcification and the risk of myocardial infarction, stroke, and peripheral arterial disease. The increasing longevity of patients with chronic comorbidities underscores the growing clinical relevance of VC.

Pathophysiology

The pathogenesis of VC is multifactorial, involving the interplay of cellular, molecular, and systemic factors. Central to this process is mineral stress signaling, a constellation of pathways activated by elevated levels of circulating calcium, phosphate, and modulators such as fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and vitamin D. Vascular smooth muscle cells (VSMCs) respond to mineral stress by undergoing osteogenic transdifferentiation, upregulating bone-related proteins such as Runx2, alkaline phosphatase, and osteopontin. This phenotypic switch is orchestrated by signaling cascades, including the Wnt/β-catenin, BMP/Smad, and PiT-1/2 phosphate transporter pathways. In parallel, inhibitors of calcification—such as matrix Gla protein (MGP) and fetuin-A—are downregulated or functionally impaired. The resultant imbalance favors ectopic mineral deposition, matrix vesicle release, and apoptosis of VSMCs, collectively driving the propagation of VC.

Risk Factors

Several risk factors potentiate the development of VC. Non-modifiable factors include advanced age, male sex, and genetic predisposition. Modifiable factors encompass chronic kidney disease, hyperphosphatemia, hypercalcemia, diabetes mellitus, hypertension, dyslipidemia, and inflammation. CKD is particularly significant, as disturbances in mineral metabolism (CKD-mineral and bone disorder, CKD-MBD) lead to sustained mineral stress and accelerated VC. Medications such as warfarin, which inhibit vitamin K-dependent carboxylation of MGP, also increase susceptibility to VC. Additional contributors include oxidative stress, uremic toxins, and metabolic acidosis, which synergistically enhance mineral stress signaling within the vasculature.

Clinical Features

VC is often clinically silent until advanced stages, when complications arise. Medial arterial calcification (Mönckeberg sclerosis) leads to increased arterial stiffness, isolated systolic hypertension, and left ventricular hypertrophy. Intimal calcification, frequently associated with atherosclerosis, predisposes to plaque rupture and thrombosis. Peripheral manifestations include intermittent claudication, poor wound healing, and critical limb ischemia. In patients with CKD, extensive VC can precipitate calciphylaxis, a life-threatening condition characterized by painful skin necrosis. Recognition of these clinical features is essential for timely diagnosis and risk stratification.

Diagnosis

Detection of VC relies on imaging modalities that visualize and quantify mineral deposits. Plain radiography is useful for identifying advanced calcification, especially in peripheral arteries. Computed tomography (CT), particularly coronary artery calcium scoring, provides a sensitive and quantitative assessment of VC burden, with prognostic significance. Other techniques include ultrasound (for carotid and peripheral arteries) and mammography (for breast arterial calcification). Laboratory evaluation of mineral metabolism (serum calcium, phosphate, PTH, FGF23, and vitamin D levels) supports the identification of underlying disturbances contributing to VC. Novel biomarkers and molecular imaging modalities are under investigation to improve diagnostic accuracy and risk prediction.

Treatment & Management

Effective management of VC focuses on controlling modifiable risk factors and optimizing mineral metabolism. In CKD, strategies include dietary phosphate restriction, use of non-calcium-based phosphate binders, and careful management of calcium and vitamin D supplementation. The use of calcimimetics, which reduce PTH and FGF23 levels, has shown benefit in attenuating VC progression. Glycemic control, blood pressure optimization, and lipid lowering are essential in diabetic and hypertensive patients. Warfarin avoidance may be considered in high-risk individuals. While no therapies directly reverse established VC, aggressive risk factor modification remains the cornerstone of management.

Recent Advances / Emerging Therapies

Recent research has identified several promising therapeutic targets within mineral stress signaling pathways. Inhibitors of sodium-dependent phosphate transporters (e.g., PiT-1/2), modulators of FGF23-Klotho axis, and agents enhancing endogenous calcification inhibitors (such as vitamin K supplementation to restore MGP activity) are under active investigation. Experimental approaches targeting osteogenic transdifferentiation of VSMCs and matrix vesicle release have demonstrated efficacy in preclinical models. Additionally, the use of bisphosphonates, sodium thiosulfate, and monoclonal antibodies against pro-calcific cytokines are being evaluated in clinical trials. These advances hold potential for transformative changes in VC management and patient outcomes.

Guideline Recommendations

Current guidelines from major nephrology and cardiology societies emphasize the importance of early identification and management of mineral metabolism disturbances in at-risk populations. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend individualized targets for serum phosphate, calcium, and PTH, with a preference for non-calcium-based phosphate binders in CKD patients. Regular assessment of VC, especially in high-risk patients, is advocated to inform therapeutic decisions. The European Society of Cardiology (ESC) guidelines integrate VC assessment into cardiovascular risk stratification, particularly in diabetic and elderly populations. Multidisciplinary collaboration is encouraged to optimize care and prevent complications associated with VC.

Conclusion

Vascular calcification represents a complex, actively regulated process driven by mineral stress signaling pathways. Its high prevalence and association with adverse cardiovascular outcomes underscore the need for heightened clinical awareness and targeted intervention. Advances in our understanding of the molecular mechanisms underlying VC have unveiled novel therapeutic opportunities, although effective reversal of established calcification remains elusive. Ongoing research and adherence to evidence-based guidelines are critical to improving the prognosis of patients affected by this challenging condition.